CUEDC2 Antibody

What are the validated applications for CUEDC2 antibodies in laboratory research?

CUEDC2 antibodies have been validated for multiple research applications, with specific protocols and dilution requirements for each method. The primary validated applications include:

• Western Blot (WB): Recommended dilution of 1:1000-1:4000

• Immunoprecipitation (IP): 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Immunohistochemistry (IHC): 1:400-1:1600 dilution

• Immunofluorescence (IF)/Immunocytochemistry (ICC): 1:50-1:500 dilution

• Flow Cytometry (FC): 0.80 μg per 10^6 cells in a 100 μl suspension

• ELISA: Typically used at 1-2 μg/ml, though optimal dilution should be determined by the researcher

It is critical to note that these recommendations serve as starting points, and researchers should optimize conditions for their specific experimental systems to obtain optimal results, as performance can vary between tissue types and cell lines.

What species reactivity has been confirmed for commercially available CUEDC2 antibodies?

Based on immunogen sequence and validation studies, commercial CUEDC2 antibodies have demonstrated reactivity with several species:

Positive Western blot detection has been specifically confirmed in multiple sample types including HepG2 cells, mouse kidney tissue, HeLa cells, human brain tissue, human kidney tissue, Jurkat cells, and mouse brain tissue . When selecting an antibody for cross-species applications, researchers should review validation data or conduct preliminary testing in their target species before proceeding with full experiments.

What is the appropriate storage and handling protocol for CUEDC2 antibodies?

Proper storage and handling of CUEDC2 antibodies is essential for maintaining reactivity and specificity:

• Storage Temperature: Store at -20°C for long-term stability

• Buffer Composition: Most CUEDC2 antibodies are supplied in PBS with additives like glycerol (typically 50%) and sodium azide (0.02-0.05%) to maintain stability

• Aliquoting: While some manufacturers note that aliquoting is unnecessary for -20°C storage, dividing the antibody into single-use aliquots is recommended to avoid repeated freeze-thaw cycles

• Stability: When properly stored, antibodies are typically stable for one year after shipment

• Light Sensitivity: For fluorophore-conjugated antibodies like CL488-20123, avoid exposure to light during storage and handling

Researchers should note that antibodies should never be exposed to prolonged high temperatures, and care should be taken to avoid repeated freeze-thaw cycles as these can significantly degrade antibody performance.

What are the recommended positive controls for validating CUEDC2 antibody specificity?

When validating a CUEDC2 antibody for experimentation, the following positive controls have been confirmed through extensive testing:

For Western Blot applications:

• HepG2 cells

• HeLa cells

• Jurkat cells

• Mouse/human brain tissue

• Mouse/human kidney tissue

For Immunofluorescence/ICC:

• HeLa cells have consistently shown positive detection

For Immunohistochemistry:

• Human ovary tumor tissue

• Human breast cancer tissue

• Human malignant melanoma tissue

For optimal IHC results, antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 may serve as an alternative. Validation should include appropriate negative controls such as isotype controls or secondary-antibody-only controls to confirm specificity.

How does CUEDC2 expression correlate with cancer progression, and what methodological approaches best characterize this relationship?

Research has revealed divergent patterns of CUEDC2 expression across cancer types, necessitating careful methodological consideration when studying its role in oncogenesis:

In lung adenocarcinoma, CUEDC2 appears to function as a tumor suppressor. Studies have demonstrated that:

• CUEDC2 is markedly down-regulated in lung adenocarcinoma tissues

• Low CUEDC2 expression correlates with advanced T classification (p = 0.001), clinical stage (p = 0.001), and larger tumor size (p = 0.033)

• Patients with low CUEDC2 expression show significantly shorter survival time (p = 0.004)

• Multivariate analysis identifies CUEDC2 expression as an independent prognostic indicator

Methodologically, researchers investigating CUEDC2 in cancer should:

• Use immunohistochemical staining of tissue microarrays to assess expression levels across patient cohorts

• Perform Kaplan-Meier survival analysis to correlate expression with patient outcomes

• Use multivariate Cox regression models to assess independent prognostic value

• Validate in vitro findings with xenograft models to confirm functional effects

Importantly, CUEDC2 expression patterns appear to be cancer-type specific, with some reports indicating high expression in breast, ovarian, and kidney cancers, contrasting with the down-regulation observed in lung adenocarcinoma . This underscores the importance of cancer-specific investigation rather than generalizing findings across tumor types.

What molecular mechanisms underlie CUEDC2's tumor-suppressive function, and how can these be effectively studied?

CUEDC2 appears to regulate tumor growth through multiple molecular pathways that can be investigated through specific methodological approaches:

In lung adenocarcinoma, CUEDC2's tumor-suppressive functions involve:

• Inactivation of the PI3K/Akt pathway

• Induction of p21 expression

• Down-regulation of cyclin D1 expression

• Inhibition of cell proliferation and colony formation

In acute myeloid leukemia (AML), CUEDC2 functions through:

• Interaction with SOCS1 protein

• Attenuation of SOCS1 ubiquitination

• Facilitation of SOCS1 stabilization by enhancing SOCS1, Elongin C, and Cullin-2 (CUL2) interactions

• Inhibition of the JAK1-STAT3 pathway activation

• Suppression of AML cell proliferation through G1 arrest

• Enhancement of AML cells' sensitivity to chemotherapeutic agents (cytarabine and idarubicin)

To study these mechanisms, researchers can employ the following methodological approaches:

• Co-immunoprecipitation assays to detect protein-protein interactions between CUEDC2 and pathway components

• Ubiquitination assays to assess SOCS1 ubiquitination levels

• Western blotting to monitor phosphorylation status of pathway components (e.g., JAK1, STAT3, Akt)

• Cell cycle analysis using flow cytometry to assess G1 arrest

• MTT and colony formation assays to assess cell proliferation

• shRNA-mediated knockdown and overexpression systems to manipulate CUEDC2 levels

• Xenograft models to confirm in vitro findings in vivo

These methodological approaches provide comprehensive insights into the molecular mechanisms by which CUEDC2 regulates tumor growth and progression.

What technical considerations should be addressed when using CUEDC2 antibodies for immunohistochemical analysis of clinical specimens?

When performing immunohistochemical analysis of CUEDC2 in clinical specimens, several critical technical considerations must be addressed:

• Antigen Retrieval Method:

  • Recommended: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0
    These specific conditions have been validated for optimal epitope exposure

• Subcellular Localization Assessment:

  • CUEDC2 is primarily localized in the cytoplasm of cells

  • Scoring systems should account for both staining intensity and percentage of positive cells

  • In lung adenocarcinoma studies, cytoplasmic localization has been confirmed as the primary pattern

• Scoring System Standardization:

  • For prognostic studies, researchers should establish clear cutoff values to define "high" versus "low" expression

  • Previous studies have used median H-scores or comprehensive scoring systems combining intensity and extent of staining

• Validation with Multiple Antibodies:

  • When possible, confirm key findings with antibodies from different sources or clones

  • Consider validating IHC results with other protein detection methods (e.g., Western blot of tissue lysates)

• Control Selection:

  • Include internal positive controls (tissues known to express CUEDC2)

  • Include adjacent normal tissue for comparison with tumor samples

  • Use appropriate negative controls including isotype controls

Adherence to these technical considerations will enhance the reliability and reproducibility of CUEDC2 immunohistochemical analyses in clinical specimens.

How can in vivo models be optimized to investigate CUEDC2's role in tumor suppression?

Based on published research, several approaches have been validated for investigating CUEDC2's function in tumor suppression using in vivo models:

These methodological approaches provide robust systems for investigating CUEDC2's tumor-suppressive functions in vivo, enhancing the translational relevance of findings from in vitro studies.

What are the potential pitfalls and troubleshooting strategies when using CUEDC2 antibodies for protein interaction studies?

When conducting protein interaction studies with CUEDC2 antibodies, researchers should be aware of several potential pitfalls and implement appropriate troubleshooting strategies:

• Co-Immunoprecipitation Challenges:

  • Pitfall: Weak or non-specific interactions

  • Strategies:

    • Use gentler lysis buffers to preserve protein complexes

    • For IP applications, use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

    • Confirm successful IP by Western blotting for CUEDC2 before probing for interaction partners

    • Cross-validation using reciprocal IP (pull down with partner antibody, detect CUEDC2)

• Specificity Concerns:

  • Pitfall: Antibody cross-reactivity with similar domains

  • Strategies:

    • Use blocking peptides (e.g., OEPB02889 for OAPB00767 antibody) to confirm specificity

    • Include negative controls (IgG or unrelated protein)

    • Validate key findings with multiple antibodies from different sources

    • Consider genetic approaches (siRNA/shRNA knockdown) to confirm specificity

• Detecting Transient or Weak Interactions:

  • Pitfall: Missing important but transient CUEDC2 interactions

  • Strategies:

    • Consider crosslinking approaches to stabilize transient interactions

    • For SOCS1-CUEDC2 interactions, examine under conditions that affect ubiquitination

    • Test interactions under different cellular stresses or stimulation conditions

• Subcellular Localization Considerations:

  • Pitfall: Interaction partners may localize to different cellular compartments

  • Strategies:

    • Use fractionation approaches to examine interactions in specific subcellular compartments

    • Perform immunofluorescence co-localization studies (1:50-1:500 dilution recommended)

    • For partners like SOCS1, examine interactions in the context of the CUL2 complex

• Technical Validation:

  • Pitfall: Artifactual interactions due to experimental conditions

  • Strategies:

    • Use multiple biochemical approaches (IP, proximity ligation assay, FRET)

    • Confirm functional relevance through genetic manipulation (e.g., demonstrate that CUEDC2 overexpression attenuates SOCS1 ubiquitination)

    • Validate interaction domains through truncation or mutation studies

These strategies will enhance the reliability and reproducibility of protein interaction studies involving CUEDC2, particularly when investigating its role in complexes regulating ubiquitination and signaling pathway modulation.

How should researchers design experiments to investigate the divergent roles of CUEDC2 across different cancer types?

Given the contrasting roles of CUEDC2 reported in different cancer types, researchers should implement a comprehensive experimental design approach:

• Expression Analysis Across Cancer Types:

  • Perform systematic analysis using tissue microarrays spanning multiple cancer types

  • Compare expression in matched tumor/normal pairs using both IHC (1:400-1:1600 dilution) and Western blotting (1:1000-1:4000 dilution)

  • Correlate with clinicopathological parameters and survival outcomes

  • Examine CUEDC2 expression in cancer databases (TCGA, GEO) for broader context

• Functional Characterization:

  • Establish panels of cell lines representing different cancer types:

    • Lung adenocarcinoma (where CUEDC2 appears tumor-suppressive)

    • Breast, ovarian, kidney cancers (where CUEDC2 may be highly expressed)

  • Perform parallel knockdown and overexpression studies across these models

  • Assess identical endpoints (proliferation, migration, invasion, drug sensitivity)

• Pathway Analysis:

  • Systematically evaluate CUEDC2's impact on key signaling pathways across cancer types:

    • JAK1-STAT3 pathway (implicated in AML)

    • PI3K/Akt pathway (implicated in lung adenocarcinoma)

    • NF-κB pathway (given CUEDC2's reported role in inflammation)

  • Use Western blotting to assess pathway component phosphorylation status

  • Employ transcriptomic approaches to identify cancer-type-specific downstream effectors

• In Vivo Validation:

  • Develop parallel xenograft models for multiple cancer types

  • Consider both subcutaneous and orthotopic models to account for microenvironment effects

  • Analyze tumors for pathway activation patterns and correlate with CUEDC2 expression

• Context-Dependent Interaction Profiling:

  • Perform immunoprecipitation studies (0.5-4.0 μg antibody for 1.0-3.0 mg lysate) to identify cancer-type-specific CUEDC2 binding partners

  • Investigate how these interactions might explain divergent functions

  • Focus on ubiquitination machinery components given CUEDC2's role in this process

This comprehensive approach will help elucidate why CUEDC2 exhibits seemingly opposite functions in different cancer contexts, potentially identifying cancer-specific cofactors or pathway interactions that determine its functional output.

What strategies can improve detection sensitivity when working with tissue samples expressing low levels of CUEDC2?

When working with samples having low CUEDC2 expression, several methodological optimizations can enhance detection sensitivity:

• Immunohistochemistry Optimization:

  • Signal Amplification: Consider tyramide signal amplification (TSA) systems

  • Antigen Retrieval: Use optimal conditions (TE buffer pH 9.0) with precise timing and temperature control

  • Detection Systems: Employ polymer-based detection rather than standard ABC methods

  • Antibody Concentration: For low-expressing samples, use the higher end of the recommended dilution range (1:400 rather than 1:1600)

  • Incubation Time: Extend primary antibody incubation to overnight at 4°C

• Western Blot Enhancement:

  • Sample Preparation: Increase protein loading (50-100 μg/lane)

  • Detection Chemistry: Use highly sensitive ECL substrates (femtogram-level detection)

  • Antibody Selection: Choose antibody lots with verified high sensitivity (1:1000 dilution)

  • Membrane Selection: Consider PVDF over nitrocellulose for better protein retention

  • Blocking Optimization: Use antibody-specific optimal blocking conditions

• Immunofluorescence Enhancement:

  • Use higher antibody concentrations (closer to 1:50 than 1:500)

  • Employ confocal microscopy with optimized laser power and detector settings

  • Consider signal enhancement via quantum dots or similar technologies

  • Use computerized image analysis for quantification of subtle differences

  • Reduce background through extended blocking and washing steps

• Enrichment Strategies:

  • Subcellular fractionation to concentrate CUEDC2 from its primary localization compartment

  • Immunoprecipitation before Western blotting for enrichment

  • Consider laser capture microdissection to isolate specific cell populations from heterogeneous tissues

These approaches can significantly improve the detection of CUEDC2 in samples with low expression levels, enabling more accurate assessment of its abundance and localization across various experimental systems.

How might CUEDC2 antibodies be utilized in developing potential prognostic or therapeutic approaches based on current molecular findings?

Based on current research findings, CUEDC2 antibodies may contribute to prognostic and therapeutic applications in several innovative ways:

• Prognostic Biomarker Development:

  • Standardized IHC protocols (1:400-1:1600 dilution) for CUEDC2 could be integrated into prognostic panels for lung adenocarcinoma, where low expression correlates with poor outcomes

  • Multivariate analysis has established CUEDC2 as an independent prognostic indicator

  • Development of automated digital pathology approaches for quantitative CUEDC2 assessment

  • Integration with other molecular markers to create comprehensive prognostic signatures

• Therapeutic Response Prediction:

  • In AML, CUEDC2 expression levels may predict sensitivity to cytarabine and idarubicin

  • CUEDC2 antibody-based assays could potentially identify patients likely to benefit from specific chemotherapy regimens

  • Monitoring CUEDC2 levels during treatment might provide early indicators of resistance development

• Pathway-Targeted Therapy Applications:

  • For cancers where CUEDC2 is down-regulated (e.g., lung adenocarcinoma):

    • Development of strategies to restore CUEDC2 expression

    • Alternative targeting of downstream pathways (PI3K/Akt inhibitors)

  • For contexts where CUEDC2-SOCS1 interaction is important:

    • Development of small molecules to stabilize this interaction

    • Targeting the ubiquitination machinery components that regulate CUEDC2 function

• Monitoring Therapeutic Response:

  • Serial tissue sampling with CUEDC2 IHC could monitor molecular response to targeted therapies

  • Development of circulating biomarkers that correlate with tissue CUEDC2 status

  • Integration into clinical trials as pharmacodynamic biomarkers

• Emerging Applications:

  • Development of highly specific monoclonal antibodies for therapeutic applications

  • Exploration of antibody-drug conjugates targeting CUEDC2 in cancers with overexpression

  • Engineered T-cell therapies (CAR-T) for cancers with differential CUEDC2 expression patterns

These applications represent potential translational developments stemming from current understanding of CUEDC2 biology, though each would require extensive clinical validation before implementation.